# Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

> **NCT06608732** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Inaticabtagene autoleucel

## Key facts

- **NCT ID:** NCT06608732
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608732, "Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06608732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*